{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:21:25Z","timestamp":1766427685799},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Interleukin (IL)-6 plays an essential role in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA). Tocilizumab (TCZ), a kind of biological agent against both membrane and soluble IL-6 receptor, is the only biological agent approved for the treatment of sJIA in China. Infections are the most common adverse events during TCZ therapy, and most of infections are mild or moderate. Severe sepsis originated from gastrointestinal infection is rarely reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>In this article, we reported two 13-year-old sJIA patients who suffered from life-threatening infections after TCZ administration. Within one day, both of them presented rapidly progressive conditions that included fever, abdominal pain, dizziness, diarrhea and vomiting, and laboratory tests showed multi-organ dysfunctions. They were diagnosed with severe sepsis and septic shock that were supposed to be caused by the pathogens from the gastrointestinal tract, and they were eventually rescued by timely treatment. In addition, we also reviewed the literature about serious gastrointestinal infections and sepsis in sJIA patients receiving TCZ therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In summary, for sJIA patients with TCZ therapy, invading pathogens from the gastrointestinal tract can cause an intensely systemic infection that may even be fatal. Therefore, it is essential to pay attention to the gastrointestinal management of sJIA patients as well as remind them of their intestinal hygiene.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12887-020-02032-w","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T12:18:09Z","timestamp":1584533889000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Meng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"issue":"7","key":"2032_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"E Mellins","year":"2011","unstructured":"Mellins E, Macaubas C, Grom A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416\u201326.","journal-title":"Nat Rev Rheumatol"},{"issue":"25","key":"2032_CR2","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"2032_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jbspin.2019.07.011","volume":"87","author":"C Dumaine","year":"2020","unstructured":"Dumaine C, Bekkar S, Belot A, Cabrera N, Malik S, von Scheven A, Carbasse A, Woerner A, Wouters C, Bouayed K, et al. Infectious adverse events in children with juvenile idiopathic arthritis treated with biological agents in a real-life setting: data from the JIRcohorte. Joint Bone Spine. 2020;87(1):49\u201355.","journal-title":"Joint Bone Spine"},{"issue":"7","key":"2032_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2018-214704","volume":"78","author":"CT Berger","year":"2019","unstructured":"Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis. 2019;78(7):1012\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2032_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14740338.2017.1303479","volume":"16","author":"SH Machado","year":"2017","unstructured":"Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4):493\u2013500.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2032_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):818\u201325.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2032_CR7","doi-asserted-by":"publisher","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"P Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281\u20138.","journal-title":"Arthritis Res Ther"},{"issue":"9617","key":"2032_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","journal-title":"Lancet"},{"issue":"4","key":"2032_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014;41(4):759\u201367.","journal-title":"J Rheumatol"},{"issue":"9","key":"2032_CR10","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75(9):1654\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2032_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2032_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","volume":"15","author":"Y Kimura","year":"2017","unstructured":"Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online J. 2017;15(1):23.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"2032_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","volume":"16","author":"M Bielak","year":"2018","unstructured":"Bielak M, Husmann E, Weyandt N, Haas JP, H\u00fcgle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, et al. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J. 2018;16(1):22.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"2032_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). Jama. 2016;315(8):801\u201310.","journal-title":"Jama"},{"issue":"18","key":"2032_CR15","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.12998\/wjcc.v7.i18.2734","volume":"7","author":"YQ Dong","year":"2019","unstructured":"Dong YQ, Wang W, Li J, Ma MS, Zhong LQ, Wei QJ, Song HM. Characterization of microbiota in systemic-onset juvenile idiopathic arthritis with different disease severities. World J Clin Cases. 2019;7(18):2734\u201345.","journal-title":"World J Clin Cases"},{"issue":"6","key":"2032_CR16","doi-asserted-by":"publisher","first-page":"G559","DOI":"10.1152\/ajpgi.00066.2017","volume":"312","author":"JP Karl","year":"2017","unstructured":"Karl JP, Margolis LM, Madslien EH, Murphy NE, Castellani JW, Gundersen Y, Hoke AV, Levangie MW, Kumar R, Chakraborty N, et al. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G559\u2013g571.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"2032_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/gut.2008.151175","volume":"59","author":"X Jin","year":"2010","unstructured":"Jin X, Zimmers TA, Zhang Z, Pierce RH, Koniaris LG. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut. 2010;59(2):186\u201396.","journal-title":"Gut"},{"key":"2032_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.","journal-title":"Front Immunol"},{"issue":"undefined","key":"2032_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Ann Rev Med. 2015;66(undefined):145\u201359.","journal-title":"Ann Rev Med"},{"issue":"1","key":"2032_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1741-7015-11-185","volume":"11","author":"C Ros\u00e1rio","year":"2013","unstructured":"Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, D\u2019Cruz DP, Shoenfeld Y. The Hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11(1):185.","journal-title":"BMC Med"},{"issue":"3","key":"2032_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, Aric\u00f2 M, Avcin T, Behrens EM, De Benedetti F, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheumatic Dis. 2016;75(3):481\u20139.","journal-title":"Ann Rheumatic Dis"},{"issue":"9","key":"2032_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","volume":"15","author":"R Cimaz","year":"2016","unstructured":"Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931\u20134.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2032_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"issue":"2","key":"2032_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, Yachie A. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287\u201394.","journal-title":"Cytokine"},{"key":"2032_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.03.023","volume":"114","author":"R Machowicz","year":"2017","unstructured":"Machowicz R, Janka G, Wiktor-Jedrzejczak W. Similar but not the same: differential diagnosis of HLH and sepsis. Crit Rev Oncol Hematol. 2017;114:1\u201312.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2032_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon EPI, Kostik M, Lovell D, Maritsi D, Nigrovic PA, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2018;70(3):409\u201319.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"2032_CR27","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, Demirkaya E, Bovis F, Li C, Lehmberg K, Weitzman S, Insalaco A, Wouters C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139.","journal-title":"Arthritis Rheumatol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02032-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-020-02032-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-020-02032-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:20:05Z","timestamp":1616026805000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-020-02032-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1186\/s12887-020-02032-w","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocols were established following the Declaration of Helsinki and approved by the Human Ethics Committee of Jilin University (Changchun, China). Written informed consent was obtained from all children\u2019s parents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details was obtained from their parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}